Naveen Bhandarkar, MD
Otolaryngic Allergy · Orange, CANPI 1205010360
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $417,304 of the $638,961 with a category attached, or 65.3%. Optinose US, Inc. accounts for 71.3% of it on its own, with 13 other manufacturers making up the rest.
Across 790 payments — averaging $808.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$455K
- Stryker$89K
- GSK$68K
- Medtronic$8K
- Regeneron Healthcare Solutions, Inc.$6K
- Acclarent, Inc$6K
- plus $8K from 8 others
Across 2 payments — averaging $20,490 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$41K
What the payments were for
- Consulting fees$91,93514%
- Speaking & faculty fees$417,30465%
- Travel & lodging$100,31516%
- Food & beverage$29,4075%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 474 | $455,384 |
| Stryker | 104 | $88,554 |
| GSK | 70 | $67,873 |
| Medtronic(2 entities) | 68 | $7,530 |
| Regeneron Healthcare Solutions, Inc. | 16 | $6,478 |
| Acclarent, Inc | 13 | $5,576 |
| Intersect ENT, Inc. | 25 | $4,885 |
| Sanofi | 1 | $832 |
| Aerin Medical Inc. | 3 | $657 |
| AstraZeneca | 7 | $520 |
| Integra Lifesciences Corporation | 5 | $429 |
| Inspire Medical Systems, Inc. | 1 | $126 |
| Novartis | 2 | $65 |
| 3-d Matrix, Inc. | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$448,465
- NUCALA$67,168
- XPRESS ENT DILATION SYSTEM$41,654
- ENTELLUS - XPRESS ENT DILATION SYSTEM$35,327
- SCOPIS ENT$34,304
- LATERA$26,838
- CLARIFIX CRYOTHERAPY DEVICE$21,297
- SHAVER SYSTEM$16,480
- TGS GUIDEWIRE$9,013
- DUPIXENT$6,755
- TruDi Nav Suction$5,300
- ACCLARENT Balloon Inflation Device$5,300
- Acclarent Navwire$4,800
- ORTHOMAP$4,000
- NUVENT$2,033
- StealthStation$1,477
- FUSION$1,224
- NASOPORE$900
- PROPEL$878
- XEROGEL NASAL/EPISTAXIS 2 PACK$800
How this compares
Too few otolaryngic allergy providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XhanceFluticasone Propionate | 133 | $92,238 |
| Azelastine Hcl | 35 | $1,424 |
| Ipratropium Bromide | 27 | $712 |
| Fluticasone Propionate | 37 | $467 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $266 |
| Levofloxacin | 15 | $164 |
| Prednisone | 22 | $73 |
| Mupirocin | 12 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $455,384 | $92,238133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngic allergy providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other otolaryngic allergy in Orange
- Edward KuanOrange$90K
- Akira IshiyamaLos Angeles$105K
- Nathalia VelasquezFremont$4K
- Mary DereberyLos Angeles$3K
- David LiuStanford$433
- Donald BurtMorgan Hill$417
- Ivor EmanuelSan Francisco$253
- Quoc NguyenGarden Grove$206
- Sidney FishmanNewport Beach$140
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.